Evidence map›Paper›PMID 27717337›Full record

ArticleBMC cancer2016

Polymorphisms in the estrogen receptor alpha gene (ESR1), daily cycling estrogen and mammographic density phenotypes.

F N Fjeldheim, H Frydenberg, V G Flote, A McTiernan, A-S Furberg, P T Ellison, E S Barrett, T Wilsgaard, G Jasienska, G Ursin and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Field cancerization in breast cancer.The Journal of pathology · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 3 countries.

F N FjeldheimThe Cancer Centre, Oslo University Hospital, Oslo, N-0424, Norway. frnfje@ous-hf.no.
H FrydenbergThe Cancer Centre, Oslo University Hospital, Oslo, N-0424, Norway.
V G FloteThe Cancer Centre, Oslo University Hospital, Oslo, N-0424, Norway.
A McTiernanFred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, USA.
A-S FurbergDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
P T EllisonDepartment of Anthropology, Harvard University, 11 Divinity Avenue, Cambridge, MA, 02138, USA.
E S BarrettDepartment of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14642, USA.
T WilsgaardDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, 9037, Tromsø, Norway.
G JasienskaDepartment of Environmental Health, Institute of Public Health, Jagiellonian University Medical College, Grzegorzecka 20, Krakow, 31-351, Poland.
G UrsinCancer Registry of Norway, PO Box 5313, Majorstuen, Oslo, N-0304, Norway.
E A WistThe Cancer Centre, Oslo University Hospital, Oslo, N-0424, Norway.
I ThuneThe Cancer Centre, Oslo University Hospital, Oslo, N-0424, Norway.
Oslo University Hospital · NOUiT The Arctic University of Norway · NOCancer Registry of Norway · NOHarvard University · USJagiellonian University · PLSeattle University · USUniversity of Oslo · NOUniversity of Rochester · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSingle nucleotide polymorphisms (SNPs) involved in the estrogen pathway and SNPs in the estrogen receptor alpha gene (ESR1 6q25) have been linked to breast cancer development, and mammographic density is an established breast cancer risk factor. Whether there is an association between daily estradiol levels, SNPs in ESR1 and premenopausal mammographic density phenotypes is unknown.

methodsWe assessed estradiol in daily saliva samples throughout an entire menstrual cycle in 202 healthy premenopausal women in the Norwegian Energy Balance and Breast Cancer Aspects I study. DNA was genotyped using the Illumina Golden Gate platform. Mammograms were taken between days 7 and 12 of the menstrual cycle, and digitized mammographic density was assessed using a computer-assisted method (Madena). Multivariable regression models were used to study the association between SNPs in ESR1, premenopausal mammographic density phenotypes and daily cycling estradiol.

resultsWe observed inverse linear associations between the minor alleles of eight measured SNPs (rs3020364, rs2474148, rs12154178, rs2347867, rs6927072, rs2982712, rs3020407, rs9322335) and percent mammographic density (p-values: 0.002-0.026), these associations were strongest in lean women (BMI, ≤23.6 kg/m

conclusionOur results support an association between eight selected SNPs in the ESR1 gene and percent mammographic density. The results need to be confirmed in larger studies.

Indexed as

Breast DensityGenetic Association StudiesPolymorphism, Single NucleotideAdultAllelesEstradiolEstrogen Receptor alphaEstrogensFemaleGenotypeHumansMenstrual CycleNorwayOdds RatioPhenotypeRisk FactorsEstradiolEstrogen Receptor alphaEstrogens17β-estradiolESR1Mammographic densityPolymorphismsPremenopausal

Identifiers

PMID27717337
PMCPMC5055696
OpenAlexW2529271376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.